TK-2504 / T-knife Therap - LARVOL DELTA

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "T-knife Therapeutics...announced it is advancing its second TCR-T program, TK-2504, toward the clinic and presented preclinical data on its ability to generate novel TCRs targeting the KRASG12V antigen....By single-cell sequencing of responding T cells, thirty distinct KRASG12V HLA-A11-restricted TCR sequences were identified. These TCRs mediated recognition of a large panel of KRASG12V-expressing cancer cell lines, as demonstrated by cytokine responses and cytotoxicity."

Preclinical • Oncology